Key result
The GAS5 rs145204276 ins/ins genotype and serum levels of TGF-β, miR-182, and SIRT-1 were significantly higher in breast cancer patients compared with healthy controls.
Why the study?
The association between the GAS5 rs145204276 ins/del polymorphism and breast cancer risk remained debated, prompting evaluation of this variant alongside SIRT-1, TGF-β, and miR-182 expression and their diagnostic value in breast cancer.
Are GAS5 rs145204276 polymorphism and serum expression of SIRT-1, TGF-β, and miR-182 associated with breast cancer?
Case-Control (n=235)
Are GAS5 rs145204276 polymorphism and serum expression of SIRT-1, TGF-β, and miR-182 associated with breast cancer?
SIRT-1, TGF-β, and miR-182 genes may serve as novel, noninvasive diagnostic biomarkers for breast cancer.
GAS5 rs145204276 may associate with BC risk; leaves open validation in larger cohorts before any clinical consideration.
Background: Breast cancer (BC) patients have a higher chance of survival if it is diagnosed at an early stage, which is essential for efficient treatment of the condition. The results of an elevated risk of cancer, including BC, previously associated with the ins/del polymorphism rs145204276 in the promoter region of growth arrest-specific 5 (GAS5) are still up for debate. Thus, this study aimed to appraise the frequency of the GAS5 rs145204276 variant with BC risk and demonstrate the potential impact of the sirtuin 1 (SIRT-1), transforming growth factor-beta (TGF-β), and microRNA-182 (miR-182) expression and their diagnostic value in BC. Methods: Blood samples of 155 patients with BC and fibroadenoma and 80 healthy controls were analyzed for GAS5 rs145204276 single nucleotide polymorphism (SNP), SIRT-1, TGF-β, and miRNA-182 expression levels. Results: Ins/ins genotype and ins allele frequencies for GAS5 rs145204276 were considerably higher in BC patients compared with controls. Patients with BC had significantly greater serum levels of TGF-β, miR-182, and SIRT-1 expression. Conclusions: The SIRT-1, TGF-β, and miR-182 genes provide novel, noninvasive diagnostic biomarkers for BC.
No takes yet. Share an insight, caveat, or question.
Hasona et al. (2024) conducted a case-control in Breast cancer (n=235). GAS5 rs145204276 polymorphism and SIRT-1, TGF-β, and miR-182 expression vs. Healthy controls was evaluated on Genotype frequencies and serum expression levels. The GAS5 rs145204276 ins/ins genotype and serum levels of TGF-β, miR-182, and SIRT-1 were significantly higher in breast cancer patients compared with healthy controls.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: